Militia Capital Management LLC Makes New Investment in Travere Therapeutics, Inc. $TVTX

Militia Capital Management LLC bought a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) in the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 29,700 shares of the company’s stock, valued at approximately $882,000.

A number of other large investors have also recently made changes to their positions in TVTX. Swiss National Bank boosted its position in Travere Therapeutics by 0.6% in the 1st quarter. Swiss National Bank now owns 168,100 shares of the company’s stock valued at $4,994,000 after buying an additional 1,000 shares during the period. Hillsdale Investment Management Inc. increased its position in shares of Travere Therapeutics by 2.9% during the first quarter. Hillsdale Investment Management Inc. now owns 182,320 shares of the company’s stock worth $5,417,000 after acquiring an additional 5,100 shares during the period. Fifth Third Bancorp purchased a new position in shares of Travere Therapeutics during the first quarter worth approximately $35,000. Hsbc Holdings PLC purchased a new position in shares of Travere Therapeutics during the first quarter worth approximately $11,788,000. Finally, Burney Co. bought a new stake in shares of Travere Therapeutics during the first quarter valued at approximately $1,180,000.

Insiders Place Their Bets

In other news, Director Timothy Coughlin sold 10,000 shares of Travere Therapeutics stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $50.07, for a total value of $500,700.00. Following the transaction, the director owned 56,250 shares of the company’s stock, valued at $2,816,437.50. The trade was a 15.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric M. Dube sold 22,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total transaction of $988,875.00. Following the transaction, the chief executive officer owned 432,886 shares of the company’s stock, valued at approximately $19,025,339.70. This trade represents a 4.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 113,413 shares of company stock worth $5,161,607. Insiders own 4.44% of the company’s stock.

Wall Street Analysts Forecast Growth

TVTX has been the topic of several research reports. Wells Fargo & Company raised their price objective on Travere Therapeutics from $50.00 to $65.00 and gave the stock an “overweight” rating in a report on Friday, June 12th. Piper Sandler upgraded Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 target price for the company in a report on Tuesday, April 14th. Wall Street Zen downgraded Travere Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Canaccord Genuity Group lifted their price objective on Travere Therapeutics from $47.00 to $56.00 and gave the company a “buy” rating in a report on Tuesday, April 14th. Finally, Weiss Ratings lowered shares of Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $52.08.

Travere Therapeutics Trading Up 0.7%

Shares of NASDAQ:TVTX opened at $56.68 on Friday. The company has a market capitalization of $5.27 billion, a PE ratio of -246.42 and a beta of 1.10. The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 3.16. Travere Therapeutics, Inc. has a 12-month low of $15.03 and a 12-month high of $60.10. The business’s fifty day simple moving average is $51.99 and its 200-day simple moving average is $39.40.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings data on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The firm had revenue of $127.20 million during the quarter, compared to analysts’ expectations of $136.23 million. During the same period in the prior year, the business posted ($0.47) EPS. The firm’s quarterly revenue was up 55.6% on a year-over-year basis. As a group, equities research analysts predict that Travere Therapeutics, Inc. will post -0.31 earnings per share for the current fiscal year.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.